Clinical Research Directory
Browse clinical research sites, groups, and studies.
DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)
Sponsor: Dizal Pharmaceuticals
Summary
This study will treat patients with DLBCL whose disease comes back or is not responding to prior therapy. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.
Official title: A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
59
Start Date
2024-03-13
Completion Date
2026-12
Last Updated
2026-03-04
Healthy Volunteers
No
Conditions
Interventions
DZD8586
Daily dose of DZD8586 at 25 mg
DZD8586
Daily dose of DZD8586 at 50 mg
DZD8586
Daily dose of DZD8586 at 75 mg
Locations (14)
Research Site
Hefei, Anhui, China
Research Site
Beijing, Beijing Municipality, China
Research Site
Guangzhou, Guangdong, China
Research Site
Nanning, Guangxi, China
Research Site
Zhengzhou, Henan, China
Research Site
Wuhan, Hubei, China
Research Site
Changsha, Hunan, China
Research Site
Jinan, Shandong, China
Research Site
Linyi, Shandong, China
Research Site
Xi’an, Shanxi, China
Research Site
Chengdu, Sichuan, China
National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, China
Research Site
Tianjin, Tianjin Municipality, China
Research Site
Hangzhou, Zhejiang, China